KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Abbott Laboratories (ABT) Operating Income (2016 - 2026)

Abbott Laboratories' Operating Income history spans 18 years, with the latest figure at $1.3 billion for Q1 2026.

  • On a quarterly basis, Operating Income fell 20.56% to $1.3 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $7.7 billion, a 8.03% increase, with the full-year FY2025 number at $8.1 billion, up 17.99% from a year prior.
  • Operating Income hit $1.3 billion in Q1 2026 for Abbott Laboratories, down from $2.3 billion in the prior quarter.
  • Over the last five years, Operating Income for ABT hit a ceiling of $2.9 billion in Q1 2022 and a floor of $1.3 billion in Q4 2022.
  • Historically, Operating Income has averaged $1.8 billion across 5 years, with a median of $1.8 billion in 2022.
  • Biggest five-year swings in Operating Income: skyrocketed 70.69% in 2022 and later plummeted 48.18% in 2023.
  • Tracing ABT's Operating Income over 5 years: stood at $1.3 billion in 2022, then surged by 36.5% to $1.8 billion in 2023, then increased by 7.36% to $1.9 billion in 2024, then grew by 17.79% to $2.3 billion in 2025, then plummeted by 40.25% to $1.3 billion in 2026.
  • Business Quant data shows Operating Income for ABT at $1.3 billion in Q1 2026, $2.3 billion in Q4 2025, and $2.1 billion in Q3 2025.